ClinicalTrials.gg
CompletedNCT00415493Updated Mar 6, 2017Results posted

Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation

An interventional study of Cold-dry air provocation and Warm-moist air provocation in Vasomotor Rhinitis, sponsored by Associated Scientists to Help Minimize Allergies. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-06.

Sponsored by Associated Scientists to Help Minimize Allergies · Not applicable, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 63 studies in Rhinitis with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Rhinitis · United States.

Enrollment
40th of 53
24 · median 64
Started
2006
with 8 others
No phase
25 of 63
1 open now
Registered
12th of 63
by date

Among the 63 studies in Rhinitis with a site in United States, this one is the 40th largest by enrollment of the 53 interventional ones that give a count, is one of 9 that started in 2006, is one of 25 with no phase, and was the 12th registered.

Rhinitis

246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.

Browse Rhinitis studies →

Open to participants now

3 of the 63 studies in Rhinitis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Rhinitis studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Rhinitis with a site in United States, or all of them as a file.
02

Study summary

This study seeks to compare patients with vasomotor rhinitis ("perennial nonallergic rhinitis," "idiopathic rhinitis") with normal controls with respect to their nasal physiologic reactivity to cold air challenge. Ten vasomotor rhinitis (VMR) patients with nasal symptoms triggered predominantly by cold air, four VMR patients with symptoms triggered predominantly by chemicals, and ten nonallergic, non-rhinitic control subjects will be studied.

Read the detailed description

After initial screening and verification that subjects can cooperate with active posterior rhinomanometry, subjects will be scheduled for two 15-minute exposure sessions with either: cold-dry air, or warm-moist air. Subjects will rate symptoms (and have their nasal airway resistance measured in triplicate) prior to exposure and at 15-min. intervals post-exposure until an hour has passed.

03

Conditions studied

  • Vasomotor Rhinitis

Keywords

  • rhinitis
  • non-allergic rhinitis
  • rhinomanometry
  • cold air
  • triggers: cold, dry air inhalation
  • warm, most air inhalation
  • Nonallergic rhinitis; normal controls
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

(cases; n = 14 total; 10 with predominantly "physical" and 4 with predominantly "irritant"triggers):

  • A significant history of chronic and/or recurrent nasal symptoms (rhinorrhea, blockage,sneezing or pruritus) in response to:

    1. Changes in temperature and/or humidity predominantly ("physical triggers"; n = 10); or
    2. Two or more nonspecific irritant triggers predominantly, including: perfumes or colognes,cleaning products, environmental tobacco smoke, vehicular exhaust, paint odors, etc. ("irritant triggers";n = 4). This history shall be of at least two years' duration.

Exclusion Criteria:

(controls; n = 10):

  • A significant history of chronic and/or recurrent nasal symptoms (rhinorrhea, blockage,sneezing or pruritus) in response to one or more nonallergic triggers, including: perfumes or colognes, cleaning products, environmental tobacco smoke, vehicular exhaust, paint odors, changes in temperature and/or humidity.

Exclusion criteria:

(all subjects; n = 24):

  • A prior history of allergic disease (allergic rhinitis, asthma, angioedema, anaphylaxis)
  • Significant skin test reactivity to one or more substances in a panel of 24 locally relevant seasonal and perennial aeroallergens
  • Negative wheal response to positive control (histamine) on skin test panel
  • Abnormalities on a screening x-ray (Waters view) of the paranasal sinuses
  • Cigarette smoking (active, within previous 6 months or cumulative history of >20 pack years)
  • Chronic cardiopulmonary diseases (asthma, , coronary artery disease...)
  • Continuous therapy with medications having antihistaminic or autonomic primary or secondary effects (e.g., oral or topical antihistamines, tricyclic antidepressants, ipratropium bromide, albuterol, alpha- or beta-adrenergic blockers...)
  • Unable to provide meaningful tracings on screening rhinomanometry.
  • Pregnancy (or planned pregnancy within 6 months); positive urinary HCG at screening visit. Patient is a breast feeding female.
  • Upper respiratory infection (common cold or sinusitis) within 2 week of screening.
  • Patient has participated in a clinical trial involving an drug within 4 weeks of visit 1.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Order 1

    Cold-dry air provocation followed (on a separate day) by Warm-moist air provocation

    Other: Cold-dry air provocation · Other: Warm-moist air provocation

  • Experimental
    Order 2

    Warm-moist air provocation followed (on a separate day) by Cold-dry air provocation

    Other: Cold-dry air provocation · Other: Warm-moist air provocation

Interventions

  • OtherCold-dry air provocation

    15 minute exposure to cold-dry air by nasal mask

  • OtherWarm-moist air provocation

    15 minute exposure to warm-moist air by nasal mask

06

What researchers measure

Primary outcomes

  1. Net Proportional Change in Nasal Airway Resistance

    Net proportional change in nasal airway resistance, pre- to post-exposure, cold air minus warm air day, calculated as a time-weighted average over the 1.0 h post-exposure. At each time point (pre-exposure, immediately post-exposure, and at 15-, 30-, 45- and 60 minutes post-exposure), nasal airway resistance (in Pa/L/sec) was measured in triplicate. The average of each of these measures was taken for each time point. The time-weighted average of these averages was then calculated for the post-exposure time points and compared with the baseline average for that individual on that testing day. The proportional change from baseline on that day was then calculated (unit-less measure). The difference between the pre-to-post change on the cold air day minus the pre-to-post change on the warm air day was then calculated (unit-less measure). The net proportional change corrects for both inter- and intra-individual variability, which in the case of nasal airway resistance is considerable.

    Time frame: One hour

07

Results

Posted Oct 26, 2012

Participant flow

Participant flow — Overall Study
MilestoneCold-dry Air Followed by Warm-moist AirWarm-moist Air Followed by Cold-dry Air
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryNet Proportional Change in Nasal Airway Resistance

Net proportional change in nasal airway resistance, pre- to post-exposure, cold air minus warm air day, calculated as a time-weighted average over the 1.0 h post-exposure. At each time point (pre-exposure, immediately post-exposure, and at 15-, 30-, 45- and 60 minutes post-exposure), nasal airway resistance (in Pa/L/sec) was measured in triplicate. The average of each of these measures was taken for each time point. The time-weighted average of these averages was then calculated for the post-exposure time points and compared with the baseline average for that individual on that testing day. The proportional change from baseline on that day was then calculated (unit-less measure). The difference between the pre-to-post change on the cold air day minus the pre-to-post change on the warm air day was then calculated (unit-less measure). The net proportional change corrects for both inter- and intra-individual variability, which in the case of nasal airway resistance is considerable.

Time frame:
One hour
Reported as:
Mean · proportional change (unit-less)
Net Proportional Change in Nasal Airway Resistance
proportional change (unit-less)CasesControls
Net Proportional Change in Nasal Airway Resistance0.11 ± 0.270.04 ± 0.16

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cases—0/14 (0%)0/14 (0%)
Controls—0/10 (0%)0/10 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CasesControlsTotal
<=18 years000
Between 18 and 65 years141024
>=65 years000
Age, Continuous
Age, Continuous(years)CasesControlsTotal
Mean36.9 ± 10.532.7 ± 14.635.1 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)CasesControlsTotal
Female10717
Male437
Region of Enrollment
Region of Enrollment(participants)CasesControlsTotal
United States141024
08

Study locations

1 site
  • ASTHMA, Inc.
    Seattle, Washington 98105, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Oct 2007 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2006
First posted
Dec 25, 2006
Start
Dec 2006
Primary completionActual
Oct 2007
CompletionActual
May 2008
Results first posted
Oct 26, 2012
Last update
Mar 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00415493
Lead sponsor
Associated Scientists to Help Minimize Allergies
Responsible party
Stephen A. Tilles MD (Executive Director, Associated Scientists to Help Minimize Allergies) — Principal investigator
First posted
Dec 25, 2006
Start date
Dec 2006
Primary completion
Oct 2007
Completion
May 2008
Results posted
Oct 26, 2012
Last update
Mar 6, 2017

Study contacts

Dennis Shusterman, MD, MPH
principal investigator · University of Washington
Stephen A Tilles,, MD
study director · ASTHMA, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion